Slides
Page 1
Sales update September 2025 YTD October 2025
Page 2
2’865 1’243 2’362 3’000 1’304 2’480 Galenica Group Products & Care Logistics & IT 09/2024 09/2025 Galenica Group Strong sales growth in the first 9 months of 2025 +4.7%Net sales (in million CHF) +5.0% +5.0% 2October 2025
Page 3
Galenica Group Sales growth supported by both segments October 2025 3 Net sales (in million CHF) 09/2025 09/2024 change Local Pharmacies 1’039 989 +5.1% Pharmacies at Home 58 57 +1.3% Retail (B2C) 1’097 1’046 +4.9% Products & Brands 142 142 +0.2% Services for Professionals 72 62 +15.9% Professionals (B2B) 214 204 +5.0% Products & Care 1’304 1’243 +5.0% Wholesale 2’375 2’263 +5.0% Logistics & IT Services 124 117 +6.4% Logistics & IT 2’480 2’362 +5.0% Corporate and eliminations -785 -740 Galenica Group 3’000 2’865 +4.7%
Page 4
989 1’039 57 58 1’046 1’097 09/2024 09/2025 Retail B2C Strong sales growth with prescription medicines 4 Net sales (in million CHF) Pharmacies at Home Local Pharmacies +4.9% +5.1% +1.3% October 2025 Portfolio of local pharmacies expanded by 5 locations: expansion impact1 of +1.7% Generics substitution rate remains with 77.7% at high level (79.2% at Dec 2024). 1) The effect of net expansion is calculated only including point of sales without a full year period comparison (acquisitions, openings and closure of pharmacies)
Page 5
109 114 33 28 142 142 09/2024 09/2025 Products & Brands Solid growth in the Swiss market 5 Net sales (in million CHF) +0.2% Swiss market International +4.6% -14.3% October 2025 Swiss market: − Growth due to expansion of1 +9.7% − Organic growth CH of -5.1% − Growth of CH market sales2 -0.4% − Market share2 of 10.7% 1) Expansion impact related new licence agreements in Jan. 2025, the effect of net expansion is calculated only including business activities without a full year period comparison (acquisitions and new license agreements) 2) Product sales to end customers of Verfora, Spagyros and Padma products (like-for-like, streetprices), IQVIA PharmaTrend for pharmacies and drugstores in Switzerland, Consumer Health market September 2025 YTD
Page 6
62 72 09/2024 09/2025 Services for professionals Strong sales growth due to expansion effects 6 Net sales (in million CHF) +15.9% − Consistent, pleasing growth with services for homecare organizations and nursing homes, negatively impacted by a decline in Winconcept sales − Growth due to expansion into diagnostics field of 12.6% October 2025
Page 7
133 137 1’473 1’553 657 686 2’263 2’375 09/2024 09/2025 Wholesale Growth in line with market development 7 Net sales (in million CHF) +2.8% +5.0% Pharmacies Physicians Others +4.4% +5.4% October 2025 Further market share gains in physicians segment
Page 8
55 55 61 69 117 124 09/2024 09/2025 Logistics & IT Services Sales growth driven by internal IT services 8 Net sales (in million CHF) October 2025 +6.4% Intercompany sales Third party sales +12.2% -0.1% Modest growth continues in IT services and pre- wholesale distribution
Page 9
Drugstores CHF 45.9 million (-4.9%) 4.3 million packs (-6.5%) Swiss pharmaceutical market September 2025 YTD 9 43.1% 4.9% 26.6% 0.8% 24.6% Physicians CHF 1,578.5 million (+4.2%) 33.5 million packs (-0.3%) Hospitals CHF 1,456.0 million (+5.5%) 11.5 million packs (-1.3%) Local Pharmacies CHF 2,558.0 million (+5.4%) 97.5 million packs (+0.9%) Total market growth CHF 5,930.2 million (+5.1%) 148.0 million packs (+0.2%) Source: IQVIA APO/SD/DRO/SPI Index, Swissmedic A, B, D Medicines Swissmedic lists A, B, D, sold from suppliers and wholesalers to hospitals, physicians, pharmacies and drugstores © IQVIA – Swiss pharmaceutical market September 2025 YTD Mail-order Pharmacies CHF 291.6 million (+8.2%) 1.3 million packs (-3.6%) October 2025
Page 10
Swiss pharmaceutical market Market YTD above last year despite one sales day less 10 Source: IQVIA APO/SD/DRO/SPI Index, Swissmedic A, B, D Medicines Swissmedic lists A, B, D, sold from suppliers and wholesalers to hospitals, physicians, pharmacies and drugstores © IQVIA – Swiss pharmaceutical market September 2025 YTD in million CHF October 2025 450 470 490 510 530 550 570 590 610 630 650 670 690 710 730 750 Jan Feb Mrz Apr Mai Jun Jul Aug Sep Okt Nov Dez 2023 2024 2025
Page 11
Consumer healthcare market September 2025 YTD 64.6% 19.8% 12.7% 2.8% OTC -0.3% Personal care -1.4% Patient care +0.9% Nutrition -1.6% 11 Total market CHF 1,930.1 million -0.4% Source: IQVIA PharmaTrend for pharmacies and drugstores in Switzerland, streetprices © IQVIA – Consumer Health market September 2025 YTD Non-medication segment -0.6% October 2025
Page 12
12 Financial guidance update 1 Excluding effects of IAS 19 and IFRS 16, see chapter “Alternative performance measures” of the Half year report 2025 , and excluding PPA-related amortization from Labor Team acquisition. adjusted due to one-off effect of CHF 5.4 million and acquisition of Labor Team Net Sales Dividend 10-12% at least at previous year’s level EBIT1 4-6% raised due to acquisition of Labor Team October 2025
Page 13
Disclaimer Disclaimer Galenica Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company’s or, as appropriate, the Company’s directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to releaseany update or revisions to any forward- looking statements in this presentation as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its of their parent or subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted develop-ments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation. Disclaimer IQVIA © 2025, IQVIA AG All rights reserved. The information may not be duplicated, stored, processed further, nor be made accessible in whole or in part to any third party without prior express and valid written permission of IQVIA AG. Terms used in connection with data/figures such as „patient”, ”doctor”, “medical practice”, ”prescriber”, or “pharmacy” do not designate any personal data but exclusively anonymous information (according to applicable, valid data protection laws). IQVIA utilizes highly sophisticated technologies and methods in order to ensure that all its Information Services meet the applicable data protection requirements, regardless of the way data are combined. 13October 2025